These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 36473323)
1. Chiral LC-MS/MS method for the simultaneous determination of (R,S)-ketamine, (R,S)-norketamine, and (2R,6R;2S,6S)-hydroxynorketamine in mouse plasma and brain. Toki H; Yamaguchi JI; Mizuno-Yasuhira A; Endo H J Pharm Biomed Anal; 2023 Feb; 224():115168. PubMed ID: 36473323 [TBL] [Abstract][Full Text] [Related]
2. Quantitative chiral and achiral determination of ketamine and its metabolites by LC-MS/MS in human serum, urine and fecal samples. Hasan M; Hofstetter R; Fassauer GM; Link A; Siegmund W; Oswald S J Pharm Biomed Anal; 2017 May; 139():87-97. PubMed ID: 28279931 [TBL] [Abstract][Full Text] [Related]
3. Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. Zhao X; Venkata SL; Moaddel R; Luckenbaugh DA; Brutsche NE; Ibrahim L; Zarate CA; Mager DE; Wainer IW Br J Clin Pharmacol; 2012 Aug; 74(2):304-14. PubMed ID: 22295895 [TBL] [Abstract][Full Text] [Related]
4. Subchronic administration of (R,S)-ketamine induces ketamine ring hydroxylation in Wistar rats. Moaddel R; Sanghvi M; Ramamoorthy A; Jozwiak K; Singh N; Green C; O'Loughlin K; Torjman M; Wainer IW J Pharm Biomed Anal; 2016 Aug; 127():3-8. PubMed ID: 27017097 [TBL] [Abstract][Full Text] [Related]
5. A parallel chiral-achiral liquid chromatographic method for the determination of the stereoisomers of ketamine and ketamine metabolites in the plasma and urine of patients with complex regional pain syndrome. Moaddel R; Venkata SL; Tanga MJ; Bupp JE; Green CE; Iyer L; Furimsky A; Goldberg ME; Torjman MC; Wainer IW Talanta; 2010 Oct; 82(5):1892-904. PubMed ID: 20875593 [TBL] [Abstract][Full Text] [Related]
6. (S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression. Yokoyama R; Higuchi M; Tanabe W; Tsukada S; Naito M; Yamaguchi T; Chen L; Kasai A; Seiriki K; Nakazawa T; Nakagawa S; Hashimoto K; Hashimoto H; Ago Y Pharmacol Biochem Behav; 2020 Apr; 191():172876. PubMed ID: 32088360 [TBL] [Abstract][Full Text] [Related]
7. Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine. Chen BK; Luna VM; LaGamma CT; Xu X; Deng SX; Suckow RF; Cooper TB; Shah A; Brachman RA; Mendez-David I; David DJ; Gardier AM; Landry DW; Denny CA Neuropsychopharmacology; 2020 Aug; 45(9):1545-1556. PubMed ID: 32417852 [TBL] [Abstract][Full Text] [Related]
8. Stereoselective and regiospecific hydroxylation of ketamine and norketamine. Desta Z; Moaddel R; Ogburn ET; Xu C; Ramamoorthy A; Venkata SL; Sanghvi M; Goldberg ME; Torjman MC; Wainer IW Xenobiotica; 2012 Nov; 42(11):1076-87. PubMed ID: 22612619 [TBL] [Abstract][Full Text] [Related]
10. A rapid and sensitive chiral LC-MS/MS method for the determination of ketamine and norketamine in mouse plasma, brain and cerebrospinal fluid applicable to the stereoselective pharmacokinetic study of ketamine. Toki H; Ichikawa T; Mizuno-Yasuhira A; Yamaguchi JI J Pharm Biomed Anal; 2018 Jan; 148():288-297. PubMed ID: 29126076 [TBL] [Abstract][Full Text] [Related]
11. Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. Farmer CA; Gilbert JR; Moaddel R; George J; Adeojo L; Lovett J; Nugent AC; Kadriu B; Yuan P; Gould TD; Park LT; Zarate CA Neuropsychopharmacology; 2020 Jul; 45(8):1398-1404. PubMed ID: 32252062 [TBL] [Abstract][Full Text] [Related]
12. The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats. Moaddel R; Sanghvi M; Dossou KS; Ramamoorthy A; Green C; Bupp J; Swezey R; O'Loughlin K; Wainer IW Pharmacol Res Perspect; 2015 Aug; 3(4):e00157. PubMed ID: 26171236 [TBL] [Abstract][Full Text] [Related]
13. Antidepressant-relevant concentrations of the ketamine metabolite (2 Lumsden EW; Troppoli TA; Myers SJ; Zanos P; Aracava Y; Kehr J; Lovett J; Kim S; Wang FH; Schmidt S; Jenne CE; Yuan P; Morris PJ; Thomas CJ; Zarate CA; Moaddel R; Traynelis SF; Pereira EFR; Thompson SM; Albuquerque EX; Gould TD Proc Natl Acad Sci U S A; 2019 Mar; 116(11):5160-5169. PubMed ID: 30796190 [TBL] [Abstract][Full Text] [Related]
17. Lack of metabolism in (R)-ketamine's antidepressant actions in a chronic social defeat stress model. Zhang K; Fujita Y; Hashimoto K Sci Rep; 2018 Mar; 8(1):4007. PubMed ID: 29507385 [TBL] [Abstract][Full Text] [Related]
18. Pharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine. Shaffer CL; Dutra JK; Tseng WC; Weber ML; Bogart LJ; Hales K; Pang J; Volfson D; Am Ende CW; Green ME; Buhl DL Neuropharmacology; 2019 Jul; 153():73-81. PubMed ID: 31015046 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic Modeling of Ketamine Enantiomers and Their Metabolites After Administration of Prolonged-Release Ketamine With Emphasis on 2,6-Hydroxynorketamines. Weiss M; Siegmund W Clin Pharmacol Drug Dev; 2022 Feb; 11(2):194-206. PubMed ID: 34265182 [TBL] [Abstract][Full Text] [Related]
20. Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model. Zhang K; Toki H; Fujita Y; Ma M; Chang L; Qu Y; Harada S; Nemoto T; Mizuno-Yasuhira A; Yamaguchi JI; Chaki S; Hashimoto K Psychopharmacology (Berl); 2018 Nov; 235(11):3177-3185. PubMed ID: 30215218 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]